New therapeutic approaches in preclinical development for thalassemias
| Drug . | Mechanisms . | Material . | Reference . |
|---|---|---|---|
| Minihepcidins | Hepcidin upregulation | Th3/+ mice | 34,35 |
| TMPRSS6-LRx | TMPRSS6 disruption | Th3/+ mice, monkeys | 36 |
| Exogenous transferrin | TfR1 downregulation | Th3/+ mice | 37 |
| ERFE downregulation | Hepcidin upregulation | Th3/+ mice | 33,36 |
| IOX1 | Selective silencing of α-globin | Erythroid cultures | 39 |
| Drug . | Mechanisms . | Material . | Reference . |
|---|---|---|---|
| Minihepcidins | Hepcidin upregulation | Th3/+ mice | 34,35 |
| TMPRSS6-LRx | TMPRSS6 disruption | Th3/+ mice, monkeys | 36 |
| Exogenous transferrin | TfR1 downregulation | Th3/+ mice | 37 |
| ERFE downregulation | Hepcidin upregulation | Th3/+ mice | 33,36 |
| IOX1 | Selective silencing of α-globin | Erythroid cultures | 39 |